SAGE Labs and CXR Biosciences have announced the development of a new service that enables researchers to better predict the risk of new pharmaceuticals, agrochemicals, and other chemicals causing carcinogenicity in humans.
SAGE Labs’ Constitutive Androstane Receptor (CAR) knockout rats form the foundation of the new assay performed by CXR, which can help determine if compounds that have been shown to cause tumours in rodents will also cause tumours in humans. The rats lack a receptor called the constitutive androstane receptor, or CAR. Compounds that activate CAR lead to the development of tumours in rodents, but do not cause tumours in humans—these rats can therefore help determine if rodent tumours observed in carcinogenicity screens are CAR mediated and therefore pose no risk to humans. CXR, the acknowledged global leader in this area of testing, typically then assesses such compounds in both human and rodent hepatocytes to verify that a compound is only carcinogenic in rodents. Full results of this work will be presented at the annual Society of Toxicology (SOT) meeting in Phoenix, Arizona, USA in March 2014.
Paul Smith, CXR CEO commented “CXR already works with many of the leading global agrochemical, chemical and pharmaceutical companies to help determine the human relevance of rodent tumours, and is acknowledged as the global expert in the use of transgenic animals and cell cultures for this purpose. This data demonstrates that the SAGE CAR KO rat is a valuable new tool to help our customers understand the safety profile of new compounds.”
Edward Weinsten, SAGE President, stated “at SAGE Labs, we’re using cutting edge genetic engineering tools that allow us to generate the most relevant and translational research models, without the limitations of conventional techniques. We’re excited to add the CAR knockout rat to our expanding line of rats for ADMET applications, which includes knockouts of the pregnane X receptor, aryl hydrocarbon receptor, and transporters such as Mdr1a and BCRP.”